ozanimod   Click here for help

GtoPdb Ligand ID: 8709

Synonyms: RPC-1063 | RPC1063 | Zeposia®
Approved drug PDB Ligand Immunopharmacology Ligand
ozanimod is an approved drug (EMA & FDA (2020))
Compound class: Synthetic organic
Comment: Ozanimod (RPC1063) is a novel, orally available, specific and potent agonist of the sphingosine 1-phosphate 1 receptor (S1P1R) and SIP5Rs [8]. Ozanimod is compound 86 in patent US20110172202 A1 [7], which specifies the (S)-enantiomer.
Ozanimod reduces chronic inflammation and alleviates kidney pathology in a mouse model of systemic lupus erythematosus (SLE), which suggests that ozanimod may offer clinical benefit as a SLE therapeutic [10].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 104.2
Molecular weight 404.18
XLogP 3.73
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES OCCNC1CCc2c1cccc2c1noc(n1)c1ccc(c(c1)C#N)OC(C)C
Isomeric SMILES OCCN[C@H]1CCc2c1cccc2c1noc(n1)c1ccc(c(c1)C#N)OC(C)C
InChI InChI=1S/C23H24N4O3/c1-14(2)29-21-9-6-15(12-16(21)13-24)23-26-22(27-30-23)19-5-3-4-18-17(19)7-8-20(18)25-10-11-28/h3-6,9,12,14,20,25,28H,7-8,10-11H2,1-2H3/t20-/m0/s1
Immunopharmacology Comments
Ozanimod is an immunomodulator that reduces isgnalling via the S1P1 and S1P5 receptors. It has been approved as an oral therapy for RMS, and is being investigated for antiinflammatory efficacy in inflammatory bowel conditions (Crohn's disease and ulcerative colitis)..
Immunopharmacology Disease
Disease X-Refs Comment References
Crohn's disease Disease Ontology: DOID:8778
OMIM: 266600
Orphanet: ORPHA206
Phase 2 clinical candidate for CD (see NCT02531113).
Ulcerative colitis Disease Ontology: DOID:8577
OMIM: 266600
Orphanet: ORPHA771
Phase 3 clinical candidate for UC (see NCT02531126).
Relapsing-remitting multiple sclerosis Disease Ontology: DOID:2378
Phase 3 clinical candidate for relapsing MS (see NCT02576717). Perliminary efficacy is reported in Celgene's Press release of Apr 24, 2018, but has yet to be confirmed. 2